# Selicrelumab

Source: https://onco.cc/drugs/selicrelumab/  
OnCo record `selicrelumab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Selicrelumab is a monoclonal antibody from Hoffmann-La Roche, in registered phase 2 trials for metastatic cancer.

## Summary

Selicrelumab is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Hoffmann-La Roche, in metastatic cancer. A monoclonal antibody: the international non-proprietary name stem -mab marks an antibody that binds one target. The registry record does not state the target unless named in the trial entries below. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Modality: Monoclonal antibody
- Mechanism: A monoclonal antibody: the international non-proprietary name stem -mab marks an antibody that binds one target. The registry record does not state the target unless named in the trial entries below.

## Sources

- ClinicalTrials.gov: trials of Selicrelumab: https://clinicaltrials.gov/search?intr=Selicrelumab

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Flatiron Health (Roche)](https://onco.cc/companies/flatiron-health/)
- trials: [A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer](https://onco.cc/trials/nct03424005/)

---
JSON: https://onco.cc/api/v1/entities/selicrelumab.json